The proposed bill aims to prohibit pharmacy benefits managers (PBMs) from obtaining certain pharmacy permits for the retail sale of drugs or medicines in Arkansas. The General Assembly recognizes the need to support patient access to affordable prescription drugs and to address anticompetitive practices that have negatively impacted locally-operated pharmacies. The bill includes legislative findings that highlight the detrimental effects of PBMs acting as both price setters and price takers, which can lead to inflated drug prices and reduced patient choices.

To implement this prohibition, the bill introduces new definitions and stipulations regarding pharmacy permits, specifically stating that PBMs cannot hold direct or indirect interests in such permits. It also outlines the responsibilities of the Arkansas State Board of Pharmacy, including the revocation or non-renewal of permits for entities that violate this section. Additionally, the bill allows for limited use permits for rare or orphan drugs that may be unavailable in the market, and it mandates written notice to pharmacy permit holders and patients regarding compliance with the new regulations. The act is set to take effect on January 1, 2026.